MedPath

JARDIANCE

These highlights do not include all the information needed to use JARDIANCE safely and effectively. See full prescribing information for JARDIANCE. JARDIANCE (empagliflozin tablets), for oral useInitial U.S. Approval: 2014

Approved
Approval ID

f2b41c77-0abb-40ee-8578-86a748d0e19e

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

May 3, 2023

Manufacturers
FDA

A-S Medication Solutions

DUNS: 830016429

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Empagliflozin

PRODUCT DETAILS

NDC Product Code50090-6457
Application NumberNDA204629
Marketing CategoryC73594
Route of AdministrationORAL
Effective DateAugust 31, 2021
Generic NameEmpagliflozin

INGREDIENTS (1)

EMPAGLIFLOZINActive
Quantity: 25 mg in 1 1
Code: HDC1R2M35U
Classification: ACTIB
© Copyright 2025. All Rights Reserved by MedPath
JARDIANCE - FDA Approval | MedPath